Tat-NR2B9c (Synonyms: Tat-NR2Bct; NA-1)

Name: Tat-NR2B9c
Brand: MedChemExpress
SKU: HY-P0117
Rating: 5.0 (9 reviews)

Cat. No.: HY-P0117 Purity: 99.97%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits?neuronal nitric oxide synthase (nNOS)/PSD-95?interaction, and possesses neuroprotective efficacy.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Tat-NR2B9c Chemical Structure

CAS No. : 500992-11-0

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water ready for reconstitution	USD 731	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in Water	USD 731	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 84	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 216	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 336	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 660	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Tat-NR2B9c:

Tat-NR2B9c TFA In-stock

8 Publications Citing Use of MCE Tat-NR2B9c

: Tat-NR2B9c purchased from MedChemExpress. Usage Cited in: J Cereb Blood Flow Metab. 2019 Aug;39(8):1588-1601. [Abstract]; Tat-NR2B9c affects PSD95-NR2B-nNOS complex and PSD95-neurexin-neuroligin complex formation after ICH. Western blots of IP with PSD95 antibody show the interactions between nNOS, NR2B, neurexin-1 or neuroligin-1, and PSD95.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All iGluR Isoform Specific Products:

View All Isoforms

AMPA Receptor NMDA Receptor Kainate Receptor

View All NO Synthase Isoform Specific Products:

View All Isoforms

nNOS iNOS eNOS

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

NMDA Receptor

nNOS

In Vitro

Tat-NR2B9c is a PSD-95 inhibitor, with an EC₅₀ of 6.7 nM for PSD-95d2, representing a >100-fold higher affinity for this domain than for PSD-95d1 (EC₅₀, 0.67 μM). Tat-NR2B9c inhibits NMDAR2A, NMDAR2B, and NMDAR2C binding to PSD-95, with IC₅₀s of 0.5 μM, ～8 μM, and 0.75 μM, respectively.
Tat-NR2B9c also blocks the interaction between PSD-95 and nNOS with an IC₅₀ of ～0.2 μM^[1].
Tat-NR2B9c reduces association of PSD-95 with GluN2B by ～50% in the YAC128 striatum, decreases NMDA-induced p38 activation in YAC128 striatal tissue, but shows no effect on the NMDA-induced JNK activation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tat-NR2B9c (10?nmol/g, i.v.) reduces infarction volume of male C57BL/6 mice, but has no effect at 3?nM/g^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

2518.88

Formula

C₁₀₅H₁₈₈N₄₂O₃₀

CAS No.

500992-11-0

Appearance

Solid

Color

White to off-white

Sequence Shortening

YGRKKRRQRRRKLSSIESDV

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (39.70 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.3970 mL	1.9850 mL	3.9700 mL
5 mM	0.0794 mL	0.3970 mL	0.7940 mL
10 mM	0.0397 mL	0.1985 mL	0.3970 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

The following protocol is derived from the literature and is for reference only. It is recommended to first try a small sample.

Protocol 1

Tat-NR2B9c is prepared in saline^[4].

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.97%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (247 KB) RP-HPLC (109 KB) MS (218 KB) Elemental Analysis Report (105 KB)

Handling Instructions (2659 KB)

References

[1]. Cui H, et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci. 2007 Sep 12;27(37):9901-15. [Content Brief]

[2]. Fan J, et al. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2012 Mar;45(3):999-1009. [Content Brief]

[3]. Teves LM, et al. Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species. J Cereb Blood Flow Metab. 2016 Mar;36(3):555-61. [Content Brief]

[4]. Jing Fan, et al. N-methyl-D-aspartate Receptor Subunit- And Neuronal-Type Dependence of Excitotoxic Signaling Through Post-Synaptic Density 9. J Neurochem. 2010 Nov;115(4):1045-56. [Content Brief]

Cell Assay ^[2]	Postnatal mono-cultured WT and YAC128 striatal neurons (DIV 9, due to the viability of these mono-cultured MSNs) are pretreated for 1 h with 200 nM Tat-NR2B9c, and/or SB-239063 (p38 inhibitor), and/or SP-600125 (JNK inhibitor), then incubated with or without 500 μM NMDA for 10 min. After NMDA treatment, striatal neurons are washed once with warm plating medium (PM) and then incubated in conditioned PM (without Tat peptides or p38, JNK inhibitors) for 24 h. Then cells are washed with PBS once and fixed with 4% paraformaldehyde (PFA) for 30 min^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice^[3] In each study mice are randomly allocated to three treatment groups (0.0, 3.0, 10.0 nMole/g Tat-NR2B9c) or to sham treatment. The individual performing the experimental procedures, administering treatments and performing the analyses is blinded to the treatment assignments. Tat-NR2B9c is prepared at the indicated doses and administered intravenously via the tail vein using a pump in a volume of 1 µL/g over 5 min beginning at reperfusion^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Cui H, et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci. 2007 Sep 12;27(37):9901-15. [Content Brief] [2]. Fan J, et al. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2012 Mar;45(3):999-1009. [Content Brief] [3]. Teves LM, et al. Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species. J Cereb Blood Flow Metab. 2016 Mar;36(3):555-61. [Content Brief] [4]. Jing Fan, et al. N-methyl-D-aspartate Receptor Subunit- And Neuronal-Type Dependence of Excitotoxic Signaling Through Post-Synaptic Density 9. J Neurochem. 2010 Nov;115(4):1045-56. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.3970 mL	1.9850 mL	3.9700 mL	9.9250 mL
	5 mM	0.0794 mL	0.3970 mL	0.7940 mL	1.9850 mL
	10 mM	0.0397 mL	0.1985 mL	0.3970 mL	0.9925 mL
	15 mM	0.0265 mL	0.1323 mL	0.2647 mL	0.6617 mL
	20 mM	0.0199 mL	0.0993 mL	0.1985 mL	0.4963 mL
	25 mM	0.0159 mL	0.0794 mL	0.1588 mL	0.3970 mL
	30 mM	0.0132 mL	0.0662 mL	0.1323 mL	0.3308 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Tat-NR2B9c Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tat-NR2B9c500992-11-0Tat-NR2Bct NA-1NA1NA 1NA-1iGluRNO SynthaseIonotropic glutamate receptorsNitric oxide synthasesNOSInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tat-NR2B9c (Synonyms: Tat-NR2Bct; NA-1)

Customer Review

Other Forms of Tat-NR2B9c:

Tat-NR2B9c Related Antibodies

8 Publications Citing Use of MCE Tat-NR2B9c

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All iGluR Isoform Specific Products:

View All NO Synthase Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Tat-NR2B9c Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tat-NR2B9c Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report